trial

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

NCTId NCT07483294
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 120 (estimated)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2029-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-11-01
Primary completion
2029-12-01
Eligibility
ALL · 15 Years · 40 Years

Interventions & indications

Drugs
RisperidoneAripiprazole

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2029-12-01
Status
RECRUITING
relationships
The graph out of here
drug
Risperidone
drug
Aripiprazole
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Psychosis; Acute
indication
Psychotic Disorders
indication